Related Experiment Videos
Urinary insulin-like growth factor-II excretion in healthy infants and children with normal and abnormal growth
T Quattrin1, C H Albini, C Sportsman
1Children's Hospital of Buffalo, Department of Pediatrics, New York.
Insights
Preterm infants and normal children excrete significantly higher urinary Insulin-like Growth Factor-II (IGF-II) than children with growth hormone deficiency or idiopathic short stature. Urinary IGF-II levels differ across these pediatric groups.
Area of Science:
- Pediatric Endocrinology
- Biochemistry
- Growth Factor Research
Background:
- Insulin-like Growth Factor-II (IGF-II) plays a crucial role in fetal and postnatal growth.
- Urinary IGF-II excretion patterns may serve as a biomarker for growth-related conditions.
- Understanding IGF-II levels in different pediatric populations is essential for diagnosing growth disorders.
Purpose of the Study:
- To quantify and compare urinary IGF-II excretion in preterm infants, full-term infants, normal children, children with growth hormone (GH) deficiency, and idiopathic short stature.
- To investigate the potential of urinary IGF-II as a diagnostic marker in pediatric growth assessment.
Main Methods:
- Radioimmunoassay (RIA) was used to measure urinary IGF-II in overnight urine samples.
- Size exclusion chromatography confirmed the authenticity of urinary IGF-II.
- Statistical analysis involved one-way ANOVA with Student Neuman-Keuls test for intergroup comparisons.
Main Results:
- Preterm and full-term infants showed significantly higher urinary IGF-II excretion than normal children (p < 0.001).
- Urinary IGF-II output was greater in preterm infants compared to full-term infants (p < 0.001).
- Normal children excreted significantly more urinary IGF-II than children with GH deficiency or idiopathic short stature (p < 0.001).
Conclusions:
- Urinary IGF-II excretion levels vary significantly across different pediatric groups, including preterm infants, full-term infants, and children with growth disorders.
- These findings suggest that urinary IGF-II may be a valuable indicator for assessing growth status and diagnosing conditions like GH deficiency and idiopathic short stature in children.
Abstract:
The output of urinary IGF-II was measured by RIA in 12-h overnight urine samples obtained from 22 preterm and 15 full-term infants, 40 normal children, 18 children with growth hormone (GH) deficiency, and 25 patients with idiopathic short stature. GH deficiency was defined as a peak to GH provocative tests < or = 9.9 micrograms/L during two provocative tests. The authenticity of urinary IGF-II was confirmed by size exclusion chromatography. Statistical analysis was performed by one-way analysis of variance using the Student Neuman-Keuls test to detect intergroup differences at the level of p < 0.05. The preterm and full-term infants excreted significantly higher amounts of urinary IGF-II (18.4 +/- 1.7 and 5.7 +/- 1.0 pmol/kg, respectively) compared with normal children (2.4 +/- 0.25 pmol/kg; p < 0.001). The output of urinary IGF-II in preterm infants was greater than that observed in full-term infants (F = 84.7, p < 0.001). The control children excreted significantly more IGF-II (2.4 +/- 0.2 pmol/kg) than children with GH deficiency (0.9 +/- 0.1 pmol/kg) or idiopathic short stature (1.0 +/- 0.1 pmol/kg; F = 13.5; p < 0.001). Analysis of urinary IGF-II excretion based on creatinine output yielded similar results. Data on urinary IGF-I and GH previously published were correlated and compared with the excretion pattern of urinary IGF-II.(ABSTRACT TRUNCATED AT 250 WORDS)